Current Report Filing (8-k)
June 03 2022 - 3:58PM
Edgar (US Regulatory)
0001559356
false
0001559356
2022-06-03
2022-06-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): |
|
June
3, 2022 (May 31, 2022) |
Immune
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Florida |
|
000-54933 |
|
59-3226705 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
|
|
|
|
|
2431
Aloma Ave,
Suite
124,
Winter
Park,
FL
| |
|
|
32792 |
(Address
of principal executive offices) |
|
|
|
(Zip
Code) |
Registrant’s
telephone number, including area code: |
|
(888)-391-9355 |
Not
Applicable
Former
name or former address, if changed since last report
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
stock $0.0001 per share |
|
IMUND |
|
OTC
Markets |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2
of the Securities Exchange Act of 1934.
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
(d) |
Election
of Directors. |
On
May 31, 2022, the following individuals were appointed to the Board of Directors of the Issuer (the “Board”) by the Board
in accordance with the bylaws of the Issuer:
Dr.
Stephen Wilson. Dr. Wilson is a trained immunologist with more than 25 years of experience in biomedical research and executive
management. He is the Chief Innovation Officer of Statera Biopharma, Inc. and an Associate Clinical Professor at the University of California,
San Diego. Prior, he served as Chief Operating Officer at the La Jolla Institute for Immunology; during his tenure the Institute grew
from $14M in annual R&D to become a global leader in immunology research with nearly $1B in total operations as well as ranked #1
place to work in the world by The Scientist magazine. His original research has been published in high impact journals, and he has served
as principal or co-principal investigator on more than $75M in competitive grants and awards, most recently developing the 2021 X-Prize
winning rapid CoVID-19 diagnostic test. Dr. Wilson has served as an advisor to elite medical research organizations, served on national
boards and is a founding scientist and board member of Invivoscribe Technologies, Inc., a leading molecular diagnostics and oncology
therapeutics company. Dr. Wilson earned his doctorate from the University of Arizona’s College of Medicine in Immunology, and was
a fellow of the National Multiple Sclerosis Society and National Institutes of Health.
Dr.
Cliff Selsky. Dr. Selsky has been a practicing pediatrician in Central Florida for the past twenty years. He is the founder of the Children’s
Center for Cancer and Blood Disease at Florida Hospital cancer institute, which he established after training in pediatrics at Yale New
Haven hospital and completing a pediatric hematology and oncology fellowship at Yale University School of Medicine. Dr. Selsky is board
certified in Pediatrics, Pediatric hematology and oncology and Palliative medicine. Currently, he is a pediatrician at Family First Pediatrics
which he established in 2013. Also, an accomplished scientist, Dr. Selsky obtained his PH.D. in Microbiology and Molecular Genetics at
the University of Miami School of Medicine. He then did DNA repair research studies at the radiobiology laboratory at Harvard School
of Public Health and the biophysics laboratory at Stanford University. Committee appointments will be made when shareholder confirmation
is complete.
Mr.
Robert Wilson. Mr. Wilson has spent more than 25 years building and launching companies. As a business strategist, retail marketer and
content developer, Robert is experienced is assessing business situations, conducting research, creating strategic plans, recommending
solutions to management, monitoring competitors, and measuring the results of marketing strategies. Robert has been involved in securing
more than $150 million in early round and angel funding, developing launch and pivot strategies, and identifying growth opportunities
for more than two dozen public companies ranging from the energy sector and electric vehicles to healthcare and lifestyle brands. Committee
appointments will be made when shareholder confirmation is complete.
Terms
under which the new Board members will be compensated have not been finalized, but new members have requested deferment of their compensation
until the Company has attained strategic funding and operational objectives.
Item
7.01. Regulation FD Disclosure.
The
issuer has filed a lawsuit in the United States District Court for the Eastern District of Virginia (Immune Therapeutics, Inc. v. Handley,
case number 3:22-cv-00412-REP) against Michael K. Handley, the former CEO, President, and Director of the Issuer, and the current CEO
and Director of Statera BioPharma Inc. The Issuer is a shareholder in Statera BioPharma Inc. A full copy of the complaint can be found
at https://pacer.login.uscourts.gov/.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
IMMUNE
THERAPEUTICS, INC. |
|
|
|
June
3, 2022 |
By:
|
/s/
Kevin J. Phelps |
|
|
Kevin
J. Phelps |
|
|
Chief
Executive Officer |
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From May 2024 to Jun 2024
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jun 2023 to Jun 2024